FierceBiotech

Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis

HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as ...
Healio

Drug costs and nocebo risks: Navigating the Humira ‘biosimilar boom’ 1 year later

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first Humira biosimilar hit the U.S. market a little ...
PharmiWeb

AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering Service for Patients” - an Initiative to Improve Patients’ Adherence to Humira® Therapy

Through providing “Humira Support Tool Ordering Service for Patients,” AbbVie, Eisai, and EA Pharma are committed to further enhancing patient support programs and contributing to improved treatment ...
Healio

Humira exclusivity expires in 2023: Will biosimilar boom benefit patients or industry?

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2021, Humira — the blockbuster biologic that has for ...
Monthly Prescribing Reference

Humira Approved for the Treatment of Non-Infectious Uveitis

AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior, and panuveitis. This approval marks the first ...
The American Journal of Managed Care

The Wait Is Over: 8 Adalimumab Biosimilars Launching in the US in July

After 7 years, competition for Humira is here. The first adalimumab biosimilar launched in January, but an additional 8, including an interchangeable product, will hit the US market in July. For ...
The American Journal of Managed Care

SmithRx to Offer Adalimumab Biosimilar Yusimry at 90% Discount to Humira

The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...
FierceBiotech

Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis

ABBOTT PARK, Ill., February 22, 2008 /PRNewswire-FirstCall/ -- Abbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market ...
Monthly Prescribing Reference

Humira Designated Orphan Drug for Painful, Inflammatory Skin Disease

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for Humira (adalimumab) as an investigational treatment for moderate-to-severe hidradenitis suppurativa ...
Seattle Times

Humira, the world’s No. 1 drug, finally faces low-cost competitors

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Alternatives to the world’s ...
Fox Business

AbbVie, Amgen Reach Settlement in Humira Patent Dispute

Drugmakers AbbVie Inc. and Amgen Inc. reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world's top-selling drug, AbbVie's arthritis ...